News

Sofosbuvir-velpatasvir combo effective in all HCV genotypes


 

References

A once-daily, fixed-dose combination of sofosbuvir (SOF) plus velpatasvir (VEL) had high success rates for the treatment of all six genotypes of hepatitis C virus, manufacturer Gilead Sciences reported.

In three of four phase III trials (ASTRAL-1, ASTRAL-2, and ASTRAL-3), 1,035 HCV patients were given the drug combination for 12 weeks. In the fourth trial (ASTRAL-4), 267 HCV patients with decompensated cirrhosis were randomized to receive either the SOF/VEL combination for 12 weeks with or without ribavirin or 24 weeks of just SOF/VEL. The primary efficacy endpoint for all studies was a sustained virological response at 12 weeks, the company said in a statement.

Courtesy US. Dept of Veterans Affairs

Results showed that 98% of patients in the first three trials achieved the efficacy endpoint. In the ASTRAL-4 study, 94% of patients in the SOF/VEL plus ribavirin group achieved sustained virological response at 12 weeks. The rates of success in patients receiving the SOF/VEL combination for 12 or 24 weeks were 83% and 86%, respectively. The most common adverse effects were fatigue, nausea, and headache.

The FDA has designated the SOF/VEL combination as “breakthrough therapy” status, granted to “investigational medicines that may offer major advances in treatment over existing options,” the statement said.

mrajaraman@frontlinemedcom.com

Recommended Reading

Smoother orthopedic implants may minimize bacterial adherence
MDedge Internal Medicine
Cefazolin outperforms nafcillin for staphylococcal bacteremia
MDedge Internal Medicine
Underweight patients showed greater mortality with gram-negative bacteremia
MDedge Internal Medicine
Delayed treatment associated with higher mortality from VRE bloodstream infections
MDedge Internal Medicine
Community hospitals harness rapid testing to slash bacteremia mortality
MDedge Internal Medicine
Septicemia due to ‘ESKAPE’ pathogens rose between 2008 and 2012
MDedge Internal Medicine
Diabetic foot ulcer: Early closure post debridement best
MDedge Internal Medicine
Send patients reminders for flu vaccines, study says
MDedge Internal Medicine
ICU care improves survival without raising costs
MDedge Internal Medicine
New assay may be a game changer in invasive candidiasis
MDedge Internal Medicine